BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38415341)

  • 1. Early-stage hepatocellular carcinoma screening in patients with chronic hepatitis B in China: a cost-effectiveness analysis.
    Nan Y; Garay OU; Lu X; Zhang Y; Xie L; Niu Z; Chen W
    J Comp Eff Res; 2024 Apr; 13(4):e230146. PubMed ID: 38415341
    [No Abstract]   [Full Text] [Related]  

  • 2. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.
    Thompson Coon J; Rogers G; Hewson P; Wright D; Anderson R; Cramp M; Jackson S; Ryder S; Price A; Stein K
    Health Technol Assess; 2007 Sep; 11(34):1-206. PubMed ID: 17767898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation and budget impact analysis of the surveillance program for hepatocellular carcinoma in Thai chronic hepatitis B patients.
    Sangmala P; Chaikledkaew U; Tanwandee T; Pongchareonsuk P
    Asian Pac J Cancer Prev; 2014; 15(20):8993-9004. PubMed ID: 25374242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic value of gamma-glutamyltransferase/aspartate aminotransferase ratio, protein induced by vitamin K absence or antagonist II, and alpha-fetoprotein in hepatitis B virus-related hepatocellular carcinoma.
    Wang Q; Chen Q; Zhang X; Lu XL; Du Q; Zhu T; Zhang GY; Wang DS; Fan QM
    World J Gastroenterol; 2019 Sep; 25(36):5515-5529. PubMed ID: 31576097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and clinical validation of a novel algorithmic score (GAAD) for detecting HCC in prospective cohort studies.
    Piratvisuth T; Hou J; Tanwandee T; Berg T; Vogel A; Trojan J; De Toni EN; Kudo M; Eiblmaier A; Klein HG; Hegel JK; Madin K; Kroeniger K; Sharma A; Chan HLY
    Hepatol Commun; 2023 Nov; 7(11):. PubMed ID: 37938100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cost-effectiveness of anti-tumor associated antigen autoantibody screening for hepatocellular carcinoma in the population with chronic hepatitis B-related cirrhosis].
    Zhang M; Li YG; Wang KY; Wang X; Dai LP; Wang P; Ye H; Shi JX; Yang XA; Zhang SX; Zhang JY
    Zhonghua Yi Xue Za Zhi; 2021 Aug; 101(32):2544-2551. PubMed ID: 34407581
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness analysis of hepatocellular carcinoma screening by combinations of ultrasound and alpha-fetoprotein among Alaska Native people, 1983-2012.
    Gounder PP; Bulkow LR; Meltzer MI; Bruce MG; Hennessy TW; Snowball M; Spradling PR; Adhikari BB; McMahon BJ
    Int J Circumpolar Health; 2016; 75():31115. PubMed ID: 27197711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis.
    Arguedas MR; Chen VK; Eloubeidi MA; Fallon MB
    Am J Gastroenterol; 2003 Mar; 98(3):679-90. PubMed ID: 12650806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic value of the γ-glutamyltransferase and alanine transaminase ratio, alpha-fetoprotein, and protein induced by vitamin K absence or antagonist II in hepatitis B virus-related hepatocellular carcinoma.
    Wang G; Lu X; Du Q; Zhang G; Wang D; Wang Q; Guo X
    Sci Rep; 2020 Aug; 10(1):13519. PubMed ID: 32782270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population health impact and cost-effectiveness of monitoring inactive chronic hepatitis B and treating eligible patients in Shanghai, China.
    Toy M; Salomon JA; Jiang H; Gui H; Wang H; Wang J; Richardus JH; Xie Q
    Hepatology; 2014 Jul; 60(1):46-55. PubMed ID: 24990105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.
    Lim TS; Kim DY; Han KH; Kim HS; Shin SH; Jung KS; Kim BK; Kim SU; Park JY; Ahn SH
    Scand J Gastroenterol; 2016 Mar; 51(3):344-53. PubMed ID: 26340708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma.
    Seo SI; Kim HS; Kim WJ; Shin WG; Kim DJ; Kim KH; Jang MK; Lee JH; Kim JS; Kim HY; Kim DJ; Lee MS; Park CK
    World J Gastroenterol; 2015 Apr; 21(13):3928-35. PubMed ID: 25852278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Online Calculator Based on Serum Biomarkers to Detect Hepatocellular Carcinoma among Patients with Hepatitis B.
    Yang T; Xing H; Wang G; Wang N; Liu M; Yan C; Li H; Wei L; Li S; Fan Z; Shi M; Chen W; Cai S; Pawlik TM; Soh A; Beshiri A; Lau WY; Wu M; Zheng Y; Shen F
    Clin Chem; 2019 Dec; 65(12):1543-1553. PubMed ID: 31672853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Hepatocellular Carcinoma Surveillance: An Assessment of Benefits and Harms.
    Parikh ND; Singal AG; Hutton DW; Tapper EB
    Am J Gastroenterol; 2020 Oct; 115(10):1642-1649. PubMed ID: 32530829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocellular carcinoma surveillance based on the Australian Consensus Guidelines: a health economic modelling study.
    Nguyen ALT; Si L; Lubel JS; Shackel N; Yee KC; Wilson M; Bradshaw J; Hardy K; Palmer AJ; Blizzard CL; de Graaff B
    BMC Health Serv Res; 2023 Apr; 23(1):378. PubMed ID: 37076870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area.
    Ungtrakul T; Mahidol C; Chun-On P; Laohapand C; Siripongsakun S; Worakitsitisatorn A; Vidhayakorn S; Boonchuay W; Dechma J; Sornsamdang G; Soonklang K; Sriprayoon T; Tanwandee T; Auewarakul CU
    World J Gastroenterol; 2016 Sep; 22(34):7806-12. PubMed ID: 27678364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation.
    Su S; Wong WC; Zou Z; Cheng DD; Ong JJ; Chan P; Ji F; Yuen MF; Zhuang G; Seto WK; Zhang L
    Lancet Glob Health; 2022 Feb; 10(2):e278-e287. PubMed ID: 35063115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha-fetoprotein, protein induced by vitamin K absence or antagonist-II, lens culinaris agglutinin-reactive fraction of alpha-fetoprotein alone and in combination for early detection of hepatocellular carcinoma from nonalcoholic fatty liver disease: A multicenter analysis.
    Guan MC; Ouyang W; Liu SY; Sun LY; Chen WY; Tong XM; Zhu H; Yang T
    Hepatobiliary Pancreat Dis Int; 2022 Dec; 21(6):559-568. PubMed ID: 35643910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of antiviral therapies for hepatitis B e antigen-positive chronic hepatitis B patients in China.
    Zhang C; Ke W; Gao Y; Zhou S; Liu L; Ye X; Yao Z; Yang Y
    Clin Drug Investig; 2015 Mar; 35(3):197-209. PubMed ID: 25672930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.